Press

MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin

Dec 1 • 2 min read

Mind Medicine Inc. (NASDAQ: MNMD), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the publication of the first data on the interaction of the selective serotonin uptake inhibitor (SSRI) escitalopram with the acute response to psilocybin in humans. The publication resulted from a randomized, double-blind, placebo-controlled, crossover pharmacology study in healthy volunteers…

Clairvoyant Therapeutics Raises More Than $3 Million in Seed Financing, Adds Bench Strength to Senior Leadership Team

Nov 30 • 5 min read

Clairvoyant Therapeutics, a Canadian biotech company focused on the development of psychedelic drug therapies for the treatment of addiction, is pleased to announce the Company has closed its initial financing round worth more than $3 million CAD. The bulk of the investment comes from four institutional investors including Iter Investments, Negev Capital, and Ambria Capital….

atai Life Sciences Increases its Ownership Position in COMPASS Pathways

Nov 30 • 4 min read

atai Life Sciences (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it has increased its ownership interest in COMPASS Pathways, from 19.4% to 20.8%. This equity stake increase is a demonstration of atai’s confidence in COMPASS Pathways and in the potential of COMP360 in mental health…

Albert Labs Receive Conditional Approval for CSE Listing & Appoint Chrystal Capital Partners to Advise on European Listing

Nov 29 • 3 min read

Albert Labs, today announced that it has received conditional approval for the listing of its common shares on the Canadian Securities Exchange (“CSE”) in coordination with its previously announced transaction with ME Resource Corp (“MEC”). Subject to final CSE approval, the Common Shares of the Company are expected to commence trading on the CSE under…

Biomind Labs Announces Design of a Pharmaceutical Form for Psychedelic Drug Delivery Using 3D Printing

Nov 29 • 2 min read

Biomind Labs Inc. (NEO: BMND), a leading biotech company in fast-acting psychedelics is pleased to announce the successful design of an oromucosal solid pharmaceutical form obtained by 3D printing using selective laser sintering. The form contains as its active ingredients certain psychedelic molecules that the Company has in its portfolio of psychedelic candidates. This pharmaceutical…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435